Compare COLD & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | LIVN |
|---|---|---|
| Founded | 1903 | 1987 |
| Country | United States | United Kingdom |
| Employees | 12690 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2009 | 2015 |
| Metric | COLD | LIVN |
|---|---|---|
| Price | $11.34 | $58.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $15.38 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 4.7M | 892.5K |
| Earning Date | 05-22-2026 | 06-01-2026 |
| Dividend Yield | ★ 8.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,601,846,000.00 | N/A |
| Revenue This Year | N/A | $9.15 |
| Revenue Next Year | $2.66 | $6.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $32.48 |
| 52 Week High | $22.36 | $71.58 |
| Indicator | COLD | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 29.55 |
| Support Level | $10.31 | $49.51 |
| Resistance Level | $13.44 | $58.91 |
| Average True Range (ATR) | 0.40 | 2.29 |
| MACD | -0.19 | -1.18 |
| Stochastic Oscillator | 6.05 | 2.15 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.